Cytek BioSciences Return on Equity

Cytek BioSciences (CTKB) currently reports a ROE of -25.27%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Cytek BioSciences's ROE history and peer comparisons.

Cytek BioSciences's ROE of -25.27% is higher than the Healthcare sector average of -75.84%. That is roughly 66.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cytek BioSciences's current -25.27% should be judged against Healthcare norms (sector average: -75.84%) and against CTKB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -25.27%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Cytek BioSciences, and consider following CTKB for alerts when major investors trade the stock.

Cytek BioSciences is classified in the Healthcare sector. On ROE, it currently shows -25.27% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CTKB with unrelated industries.